Fitaro 1.7 mg/0.75 ml is an advanced injectable formulation containing Semaglutide, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. It is designed for the management of type 2 diabetes mellitus and chronic weight management in adults. Fitaro works as an adjunct to diet and exercise to improve glycemic control and has also demonstrated cardiovascular benefits in patients with established cardiovascular disease.

Semaglutide mimics the action of natural GLP-1, a hormone involved in glucose regulation and appetite control. By enhancing glucose-dependent insulin secretion, suppressing inappropriate glucagon release, and slowing gastric emptying, Fitaro helps achieve sustained blood glucose control while promoting weight reduction. Its once-weekly dosing schedule improves patient adherence and convenience compared to daily therapies.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Fitaro 1.7 mg/0.75 ml is indicated:

• As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

• To reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease

• As an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with:

  • Body mass index (BMI) ≥ 30 kg/m² (obesity), or

  • BMI ≥ 27 kg/m² (overweight) with at least one weight-related comorbid condition such as hypertension, dyslipidemia, or type 2 diabetes

Therapeutic Class

GLP-1 receptor agonists

Composition

Each pre-filled syringe contains semaglutide solution for injection in varying strengths:

• 0.25 mg in 0.5 ml

• 0.5 mg in 0.5 ml

• 1 mg in 0.5 ml

• 1.7 mg in 0.75 ml

• 2.4 mg in 0.75 ml

Pharmacology

Semaglutide is a GLP-1 analogue with high structural similarity to human GLP-1. It selectively activates GLP-1 receptors, leading to glucose-dependent insulin secretion and suppression of glucagon release. Albumin binding and resistance to DPP-4 degradation prolong its half-life, allowing once-weekly administration. These mechanisms collectively improve glycemic control and support weight reduction.

Dosage & Administration

Fitaro is administered as a subcutaneous injection once weekly, with gradual dose escalation to improve tolerability:

• Weeks 1–4: 0.25 mg

• Weeks 5–8: 0.5 mg

• Weeks 9–12: 1 mg

• Weeks 13–16: 1.7 mg

• Maintenance (Week 17 onward): 2.4 mg

If intolerance occurs, dose escalation may be delayed or temporarily reduced. Injections may be given in the abdomen, thigh, or upper arm, with or without meals.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Drug Interactions

When used with insulin or insulin secretagogues such as sulfonylureas, dose reduction of the concomitant drug may be required to reduce the risk of hypoglycemia. Caution is advised with orally administered medications.

Contraindications

Fitaro is contraindicated in patients with:

• Personal or family history of medullary thyroid carcinoma

• Multiple Endocrine Neoplasia syndrome type 2

• Known hypersensitivity to semaglutide or formulation components

Side Effects

Common adverse effects include gastrointestinal symptoms such as nausea, vomiting, diarrhea, and decreased appetite. Serious but rare risks include pancreatitis and thyroid C-cell tumors.

Pregnancy & Lactation

Use during pregnancy is not recommended unless clearly needed. Breastfeeding should be discontinued during treatment due to potential risk to the infant.

Storage Conditions

Store refrigerated at 2°C to 8°C. Do not freeze. After first use, the pen may be stored for up to 56 days under recommended conditions.